ACH ACCENDRA HEALTH INC/VA/
Wholesale-Medical, Dental & Hospital Equipment & Supplies · OTC · SEC CIK 75252 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.0%
TTM net income YoY-195.8%
TTM EPS YoY-195.6%
Revenue 3-yr CAGR-35.4%
Net income 3-yr CAGR—
Margins
Gross margin46.0%
Operating margin0.9%
Net margin-39.8%
FCF margin-10.7%
EBITDA margin8.2%
Returns
ROE-2,037.6%
ROA-29.8%
ROIC (approx.)1.0%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets119.2%
Debt / equity—
Current ratio0.49x
Interest coverage0.22x
Cash quality & payout
Operating cash flow / net income0.11x
Accruals ratio-26.5%
Payout ratio—
Capex / revenue6.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $601.77M | $613.23M | $627.78M | $708.97M | $697.26M | $681.92M | $673.88M | $695.02M |
| Cost of revenue | $340.47M | $349.83M | $349.75M | $385.71M | $375.07M | $357.31M | $354.64M | $362.03M |
| Gross profit | $261.31M | $263.41M | $278.03M | $323.26M | $322.20M | $324.60M | $526.01M | $579.77M |
| SG&A expense | $249.46M | $243.56M | $255.23M | $271.50M | $265.84M | $267.85M | $262.37M | $269.89M |
| Operating income | $1.33M | -$35.15M | $17.12M | $20.91M | $26.47M | -$39.71M | $19.79M | -$272.70M |
| Interest expense | $37.62M | $34.54M | $32.35M | $27.93M | $29.03M | $26.01M | $24.21M | $27.62M |
| Pretax income | -$36.82M | -$87.63M | -$16.25M | -$7.97M | -$3.63M | -$84.95M | -$5.40M | -$302.04M |
| Income tax | -$18.86M | $1.44M | -$9.78M | $1.47M | $1.97M | -$1.13M | -$1.59M | $29.82M |
| Net income | -$19.70M | -$89.07M | -$6.47M | -$56.33M | -$150.28M | -$869.06M | -$24.98M | -$296.12M |
| EBITDA | $40.25M | $30.55M | $78.87M | $50.78M | $90.57M | $3.28M | $62.69M | -$207.51M |
| EPS (basic) | -0.25 | -1.16 | -0.08 | — | -1.94 | -11.30 | -0.32 | — |
| EPS (diluted) | -0.25 | -1.16 | -0.08 | — | -1.94 | -11.30 | -0.32 | — |
| Weighted avg. shares (diluted) | 76.91M | 76.69M | 76.43M | — | 77.29M | 76.94M | 77.27M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $26.61M | $7.65M | $336.88M | $281.99M | $32.84M | $38.26M | $59.44M | $27.57M |
| Inventory | $82.10M | $73.34M | $65.28M | $74.44M | $63.85M | $69.23M | $1.41B | $67.58M |
| Current assets | $273.92M | $271.45M | $588.50M | $547.87M | $2.13B | $2.30B | $2.21B | $2.02B |
| PP&E, net | $218.24M | $208.67M | $227.73M | $256.16M | $259.73M | $259.30M | $520.33M | $249.28M |
| Goodwill | $1.23B | $1.23B | $1.23B | $1.23B | $1.23B | $1.23B | $1.33B | $1.23B |
| Intangibles | $73.03M | $78.01M | $107.24M | $136.47M | $165.69M | $194.92M | $285.09M | $210.06M |
| Total assets | $2.08B | $2.11B | $2.42B | $2.45B | $4.04B | $4.15B | $4.86B | $4.66B |
| Current liabilities | $671.50M | $666.22M | $1.20B | $947.08M | $2.47B | $2.67B | $1.96B | $1.85B |
| Short-term debt | $35.00M | $0 | $581.25M | $250.00M | $280.00M | $383.00M | $49.95M | $42.87M |
| Long-term debt | $1.72B | $1.72B | $1.52B | $1.80B | $1.84B | $1.59B | $1.90B | $1.80B |
| Total debt | $1.75B | $1.72B | $2.10B | $2.05B | $2.12B | $1.98B | $1.95B | $1.84B |
| Total liabilities | $2.65B | $2.66B | $2.88B | $2.91B | $4.47B | $4.44B | $4.29B | $4.07B |
| Shareholders' equity | -$568.23M | -$550.94M | -$464.76M | -$460.98M | -$429.51M | -$281.01M | $570.98M | $586.36M |
| Net debt | $1.73B | $1.71B | $1.77B | $1.77B | $2.08B | $1.94B | $1.89B | $1.81B |
| Shares outstanding | 76.92M | 76.91M | 76.58M | 76.39M | 77.30M | 77.20M | 77.22M | 77.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$17.41M | -$26.01M | -$50.08M | $68.19M | -$172.52M | $37.61M | -$35.07M | $71.00M |
| Capital expenditure | $39.16M | $47.59M | $41.65M | $13.13M | $42.13M | $77.78M | $45.79M | $22.25M |
| Free cash flow | -$56.58M | -$73.59M | -$91.72M | $55.05M | -$214.65M | -$40.17M | -$80.86M | $48.75M |
| Investing cash flow | $5.77M | -$31.25M | $53.92M | $285.00M | -$39.46M | -$52.92M | -$48.20M | -$52.30M |
| Financing cash flow | $30.60M | -$271.98M | $51.08M | -$117.50M | $181.10M | $31.70M | $92.78M | -$43.10M |
| Depreciation & amortization | $38.92M | $65.70M | $61.74M | $29.87M | $64.10M | $42.99M | $42.90M | $65.19M |
| Stock-based compensation | $2.11M | $4.00M | $3.09M | -$4.46M | -$168,000 | $4.87M | $4.42M | $7.55M |
| Share buybacks | — | — | $0 | $3.52M | $0 | $5.15M | $1.50M | — |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.